<DOC>
	<DOCNO>NCT01707082</DOCNO>
	<brief_summary>Part A study test safety , amount drug body , effect drug body multiple dos . This conduct healthy overweight adult . Part B study test effect multiple dos investigational drug amount midazolam , approve drug , healthy adult .</brief_summary>
	<brief_title>A Study To Test The Safety , Amount And Effects Of PF-06282999 In Healthy Overweight Adults And A Study To Test The Effects Of PF-06282999 On The Amount Of The Approved Drug , Midazolam , In Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Women must non childbearing potential . Body Mass Index ( BMI ) 27.0 35.0 kg/m2 ( Part A ) 17.5 30.5 kg/m2 ( Part B ) ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include clinically significant drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Subject contraindication midazolam accord country specific label subject previous intolerance allergy benzodiazepine ( applicable Part B study ) . Subjects enrol Part A excluded participation Part B study . Subjects previously participate study PF06282999 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>